ScholarLens Back to search
2013•BloodRequires access

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

Giovanni Francesco D'Arena, Roberto Guariglia, Giovanna Mansueto, Maria Carmen Martorelli, Giuseppe Pietrantuono, Oreste Villani, Rosa Lerose, Pellegrino Musto

Open publisher page 23 citations

Abstract

To the editor: Romiplostim and eltrombopag (a synthetic fusion peptibody and a nonpeptide molecule, respectively) are second-generation thrombopoietin mimetics/agonists that are structurally dissimilar to thrombopoietin and do not induce the formation of autoantibodies.[1][1][⇓][2]–[3][3] They

About this research paper

What this paper is about

To the editor: Romiplostim and eltrombopag (a synthetic fusion peptibody and a nonpeptide molecule, respectively) are second-generation thrombopoietin mimetics/agonists that are structurally dissimilar to thrombopoietin and do not induce the formation of autoantibodies.[1][1][⇓][2]–[3][3] They

Why it matters

OpenAlex reports 23 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To the editor: Romiplostim and eltrombopag (a synthetic fusion peptibody and a nonpeptide molecule, respectively) are second-generation thrombopoietin mimetics/agonists that are structurally dissimilar to thrombopoietin and do not induce the formation of autoantibodies.[1][1][⇓][2]–[3][3] They

Key concepts: Romiplostim, Eltrombopag, Thrombopoietin, Thrombopoietin receptor, Thrombocytopenic purpura, Medicine, Immunology, Autoantibody

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura — Research Paper | ScholarLens